Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: A crossover study in patients with gastro-oesophageal reflux disease

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 7, 2003, Pages 791-799

  Simon, Bernd ^a   Müller, Peter ^b   Pascu, Oliviu ^c   Gatz, Gudrun ^d   Sander, Peter ^d   Huber, Reinhard ^d   Mascher, Hermann ^e  

^a Kreiskrankenhaus Schwetzingen   (Germany)

^b Krankenhaus Salem   (Germany)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d ALTANA Pharma   (Germany)

^e Pharmanalyt GmbH   (Austria)

Author keywords

Esomeprazole; Gastric acid; Gastro oesophageal reflux disease; GORD; Pantoprazole; PH metry; Proton pump inhibitor

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; SULFOXIDES;

EID: 0037488316     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200307000-00011     Document Type: Article

References (28)

1. Carlsson R, Holloway RH. Endoscopy-negative reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:827-837.
2. Huang JQ, Hunt RH. pH, healing rate and symptom relief in patients with GERD. Yale J Biol Med 1999; 72:181-194.
3. Tolman KG, Chandramouli J, Fang JC. Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 2000; 1:1171-1194.
4. Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther 2000; 22:1268-1293.
5. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994; 8 (suppl 1):39-46.
6. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95:3071-3080.
7. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14:861-867.
8. Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60:321-329.
9. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51:460-482.
10. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22:266-280.
11. Koop H, Kuly S, Flüs M, Schneider A, Rose K. Comparison of 24 h intragastric pH and 24 h gastrin profiles during therapy with proton pump inhibitors pantoprazole and omeprazole [Abstract]. Gut 1994; 35 (suppl 4):79.
12. Brunner G, Danz-Neeff H, Athmann C, Samayoa N. Comparison of pantoprazole (40 mg sid) versus omeprazole (40 mg sid) on intragastric pH and serum gastrin in healthy volunteers [Abstract]. Gastroenterology 1996; 112 (suppl 4):78.
13. Patti MG, Diener U, Tamburini A, Molena D, Way LW. Role of esophageal function tests in diagnosis of gastroesophageal reflux disease. Dig Dis Sci 2001; 46:597-602.
14. Regulile de buna practice in studiul clinic. Ordinul Ministerului Sanatatii Nr. 858/19.X.1997.2002.
15. Huber R, Muller W, Banks MC, Rogers SJ, Norwood PC, Doyle E. High-performance liquid chromatographic determination of the H+/K+ ATPase inhibitor (BY 1023/SK&F 96,022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up. J Chromatog 1990; 529:389-401.
16. Sauter R, Steinijans VW, Diletti E, Bohm A, Schulz HU. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992; 30:233-256.
17. Hartmann M, Ehrlich A, Fuder H, Lühmann R, Wieckhorst G, Wurst W, Lücker PW. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998; 12:1027-1032.
18. Hartmann M, Theiss U, Huber R, Lühmann R, Bliesath H, Wurst W, Lücker PW. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10:359-366.
19. Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15:1563-1569.
20. Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56:665-670.
21. Mearin F, Balboa A, Dot J, Maldonado O, Malagelada JR. How standard is a standard day during a standard ambulatory 24-hour esophageal pH monitoring? Scand J Gastroenterol 1998; 33:583-585.
22. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (suppl 1):59-67.
23. Weusten BL, Roelofs JM, Akkermans LM, Vanberge-Henegouwen GP, Smout AJ. Objective determination of pH thresholds in the analysis of 24 h ambulatory oesophageal pH monitoring. Eur J Clin Invest 1996; 26:151-158.
24. Labenz J, Tillenburg B, Peitz U, Idstrom JP, Verdu EF, Stoke M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110:725-732.
25. Cederberg C, Rohss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 28:179-184.
26. Ching MS, Mihaly GW, Angus PW, Morgan DJ, Devenish-Meares S, Yeomans ND, Smaliwood RA. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991; 31:166-170.
27. Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991; 3:45-52.
28. Ehrlich A, Lücker PW, Wiedemann A, Sander P, Huber R, Mascher H. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol 1999; 21:47-51.